BioBricks
South Korean bioprinting company developing tissue-specific bioinks (OrganINK) and regenerative therapies for corneal ulcers and artificial organs.
- CEO / Founder
- Jinah Jang (장진아)
- Team Size
- 11-50
- Stage
- Early Stage
- Total Funding
- $1.5M
- Latest Round
- Seed
- Key Investors
- 페이서 파트너스; POSTECH
Technology & Products
Key Products
OrganINK (liquid dECM-based bioink for 3D bioprinting); GelCODE (regenerative therapy for corneal ulcers); Cornea-specific bioink for corneal reconstruction; Heart patch for myocardial regeneration
Technical position · AMPulse analysis
World-class dECM bioink technology developed at POSTECH with 18+ technology transfers; automated decellularization process for scalable manufacturing; first-mover in cornea-specific regenerative bioink with large animal study validation.
Differentiation
Value Proposition
Tissue-specific decellularized extracellular matrix (dECM)-based bioinks that replicate native tissue microenvironments for 3D bioprinting of functional tissues and organs.
How They Differentiate
Proprietary decellularization automation system producing OrganINK bioinks that are tissue-specific, immune-compatible (a-gal removed), and scalable for manufacturing. Unlike competitors using synthetic or generic hydrogels, BioBricks' bioinks match the native ECM composition of target organs.
Market & Competition
Target Customers
Hospitals and clinics (corneal ulcer treatment); pharmaceutical companies (drug testing platforms); medical device companies; research institutions
Industry Verticals
Regenerative Medicine; Ophthalmology; Cardiology; Tissue Engineering; Drug Development
Competitors
CELLINK (Sweden/US); Aspect Biosystems (Canada); T&R Biofab (South Korea)
Growth & Milestones
Major Milestones
2022: Company founded; 2023: Pre-A funding round; 2023: Won K-Tech Startup King Competition Excellence Award; 2024: Won 'Challenge! K-Startup 2024' Grand Prize (Presidential Award); 2024: MOU with ThreeBrooks for animal-alternative drug toxicity testing; 2025: Planning Series A funding round (~₩10B); 2025: Human clinical trials for corneal ulcer treatment targeted
Recent coverage of BioBricks
AM patents
AM-relevant patents linked to this company.
- Patents
- 1
- Granted
- 0
- Families
- 1
Leading domains: application (1), process (1)
Filings by year: 2023: 1
- 보형물 삽입 수술에 이용되는 약물전달 패치 및 이의 제조방법1029897380000 · KR
Funding rounds
- SeedUndisclosed2024-06Lead: 페이서 파트너스 · Source: 넥스트유니콘
- Seed₩500M2022-05Lead: POSTECH · Source: PitchBook